Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020

Rhea-AI Summary

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced that it will release its third quarter fiscal year 2020 financial results on November 12, 2020, after market close. A conference call is scheduled for 5:45 p.m. ET the same day to discuss these results. Interested parties can join the call or access a live webcast via the company’s investor relations website. Helius focuses on developing non-invasive neurotechnology aimed at enhancing neurological wellness, with its leading product, the Portable Neuromodulation Stimulator (PoNS™), currently authorized for sale in Canada but still investigational in other markets.

Positive

• Scheduled release of third quarter fiscal year 2020 financial results indicating ongoing transparency and engagement with investors.
• The company is focused on innovative neurotechnology aimed at improving neurological wellness, which could drive future growth.

Negative

• The PoNS device is currently only authorized for sale in Canada, limiting market potential.
• PoNS treatment remains investigational in the U.S. and other key markets, which may hinder revenue generation.

NEWTOWN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter of fiscal year 2020 financial results will be released after the market closes on Thursday, November 12th.

Management will host a conference call at 5:45 p.m. Eastern Time on November 12th to discuss the results of the quarter. Those who would like to participate may dial 877-407-2988 (201-389-0923 for international callers) and provide access code 13711025. A live webcast of the call will also be provided on the Events section of the Company's investor relations website and can be accessed directly via the following link: https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/40996/indexl.html.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13711025. The webcast will be archived on the Events section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Treatment

The Portable Neuromodulation Stimulator (PoNS) is an authorized class II, non-implantable medical device authorized for sale in Canada. PoNS is intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy and indicated as a short term treatment (14 weeks) chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The PoNS is an investigational medical device in the United States, the European Union, and Australia, and is currently under review for clearance by the FDA and AUS Therapeutic Goods Administration. PoNS Treatment is currently not commercially available in the United States, the European Union or Australia.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.

Mike Piccinino, CFA

investorrelations@heliusmedical.com

FAQ

When will Helius Medical Technologies release its third quarter financial results?

Helius Medical Technologies will release its third quarter financial results on November 12, 2020, after market close.

What is the focus of Helius Medical Technologies?

Helius Medical Technologies focuses on developing non-invasive technologies aimed at enhancing neurological wellness.

Is the Portable Neuromodulation Stimulator (PoNS) available in the United States?

No, the PoNS device is currently investigational in the United States and is not commercially available.

What is the significance of the PoNS device?

The PoNS device is designed to treat gait deficits due to multiple sclerosis and balance deficits from traumatic brain injuries.

How can I access the conference call on November 12, 2020?

You can participate in the conference call by dialing 877-407-2988 and providing the access code 13711025.